Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/13/2017 |
| Start Date: | March 2005 |
| End Date: | July 2007 |
Selegiline for Treatment of Cannabis Dependence
During the past 15 years, the demand for treatment for marijuana-related problems in the
United States has increased nearly twofold. Selegiline is a medication currently used to
treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may
be useful in treating individuals with marijuana dependence.
United States has increased nearly twofold. Selegiline is a medication currently used to
treat nicotine dependence. The purpose of this study is to evaluate whether selegiline may
be useful in treating individuals with marijuana dependence.
Behavioral therapy paired with drug therapy might be a more effective treatment approach to
marijuana dependence than behavioral therapy alone. Selegiline is a monoamine oxidase-B
inhibitor. It increases dopamine activity in parts of the brain that are involved in
dependence on addictive drugs such as nicotine, cocaine, and marijuana. Selegiline has been
effective in treating nicotine dependence, but has not yet been studied in treating
marijuana dependent individuals. The purpose of this study is to evaluate the effectiveness
of selegiline in treating marijuana dependent individuals. Specifically, this study will
determine whether selegiline reduces marijuana craving and withdrawal symptoms, thus leading
to reduction or abstinence in marijuana use.
Participants in this 9-week, double-blind, placebo-controlled study will be randomly
assigned to receive either selegiline (10 mg/day in two 5 mg pills) or placebo. Study visits
will occur twice each week. At each study visit, participants will complete self-reports and
urine toxicology tests. Throughout the study, participants will receive weekly individual
counseling. The counseling sessions will last 15 minutes. Reduction in marijuana use as well
as the number of weeks of consecutive marijuana abstinence will be evaluated.
marijuana dependence than behavioral therapy alone. Selegiline is a monoamine oxidase-B
inhibitor. It increases dopamine activity in parts of the brain that are involved in
dependence on addictive drugs such as nicotine, cocaine, and marijuana. Selegiline has been
effective in treating nicotine dependence, but has not yet been studied in treating
marijuana dependent individuals. The purpose of this study is to evaluate the effectiveness
of selegiline in treating marijuana dependent individuals. Specifically, this study will
determine whether selegiline reduces marijuana craving and withdrawal symptoms, thus leading
to reduction or abstinence in marijuana use.
Participants in this 9-week, double-blind, placebo-controlled study will be randomly
assigned to receive either selegiline (10 mg/day in two 5 mg pills) or placebo. Study visits
will occur twice each week. At each study visit, participants will complete self-reports and
urine toxicology tests. Throughout the study, participants will receive weekly individual
counseling. The counseling sessions will last 15 minutes. Reduction in marijuana use as well
as the number of weeks of consecutive marijuana abstinence will be evaluated.
Inclusion Criteria:
- Meets DSM-IV criteria for current marijuana dependence
- Positive urine toxicology test for marijuana
- Reports current marijuana use
- Weighs at least 100 lbs
- Women of childbearing age will be included provided they agree to use adequate
contraception
Exclusion Criteria:
- Meets dependence or abuse criteria for alcohol
- Meets dependence criteria for illicit substances other than marijuana
- Serious medical disorders (such as unstable angina or liver failure), that may make
participation in the trial unsafe
- Pregnant
- Currently diagnosed with a psychotic disorder
- Currently suicidal or pose a homicidal risk
- Currently taking over-the-counter (e.g., pseudoephedrine) or prescription (e.g.,
methylphenidate) sympathomimetic agents, antidepressant agents (e.g., tricyclic
antidepressants, serotonin reuptake inhibitors, bupropion, other monoamine oxidase
inhibitors), or meperidine (Demerol)
- Unable to understand English
- Known hypersensitivity to selegiline hydrochloride
We found this trial at
1
site
